EU AstraZeneca Ruling — A Letdown For Life Sciences Cos.

Law360, New York (December 21, 2012, 1:13 PM EST) -- On Dec. 6, 2012, the EU Court of Justice dismissed AstraZeneca's appeal of the General Court's judgment in AstraZeneca PLC. v. Commission.[1] The Court of Justice affirmed the reasoning and holdings of the General Court and rejected all of AstraZeneca's arguments, including its challenge to the General Court's analysis of the definition of the relevant markets and the findings that AstraZeneca's intellectual property and regulatory strategies related to its product Losec constituted an abuse of a dominant position in violation of Article 102 TFEU....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!